Remdesivir less expensive for ‘government programs.’ Not so fast
Remdesivir is an investigational antiviral drug that recently gained prominence as the only drug authorized for emergency use against COVID-19. On Monday, Gilead revealed its pricing plans in the U.S., charging hospitals $3,120 for a typical patient. Additionally, Dan O’Day, the CEO of Gilead, promised on CNBC and in an open letter that Remdesivir would have a lower “government price” in the U.S. for a five-day course. However, the discount will only apply to a select group of smaller government programs, excluding Medicare and Medicaid. Dr. Peter Bach proposes two options if Gilead wishes to discount Remdesivir to the full array of government programs.
Read the data brief here.